Company

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised
Finanical ReportsHKG: 2359

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359) released its 2026 third-quarter report, posting Q3 operating revenue of RMB 16.640 billion, up 38.01% year on year (YoY), and net profit…

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist
AbbVieHengrui Pharmaceuticals

Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist

Johnson & Johnson Announces International Withdrawal of Linx Reflux System
J&JJohnson & Johnson

Johnson & Johnson Announces International Withdrawal of Linx Reflux System

RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes
Cell-therapyClinical trial approval / initiation

RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes

Jiangsu Hengrui’s Adebrelimab New Indication Accepted by NMPA for Stage II‑IIIB NSCLC
CancerHengrui Pharmaceuticals

Jiangsu Hengrui’s Adebrelimab New Indication Accepted by NMPA for Stage II‑IIIB NSCLC

Show More